Promising New Non-Hormonal Treatment for Endometriosis Enters Phase II Trials
Berlin, Germany – March 13, 2026 – Gesynta Pharma has begun dosing patients in its Phase II NOVA trial, evaluating vipoglanstat as a potential new treatment for endometriosis. This marks a significant step forward in the development of a non-hormonal, non-opioid therapy for a condition affecting an estimated 190 million women globally. Endometriosis, a chronic inflammatory disease, can cause debilitating pain and significantly impact quality of life, and current treatment options often come with substantial side effects or limited efficacy. The initiation of this trial offers hope for a more targeted and tolerable approach to managing the disease.
Endometriosis occurs when tissue similar to the lining of the uterus grows outside of it, most commonly on the ovaries, fallopian tubes, and pelvic lining. This misplaced tissue responds to hormonal changes during the menstrual cycle, causing inflammation, pain, and potentially infertility. Symptoms can vary widely in severity, ranging from mild discomfort to excruciating pain that interferes with daily activities. Diagnosis often involves a significant delay, with many women experiencing years of suffering before receiving a definitive diagnosis. The lack of effective, well-tolerated treatments underscores the urgent necessitate for innovative therapies like vipoglanstat.
Understanding Vipoglanstat’s Mechanism of Action
Vipoglanstat is a novel drug designed to target microsomal prostaglandin E synthase-1 (mPGES-1), an enzyme crucial in the production of prostaglandin E2 (PGE2). PGE2 plays a significant role in the inflammatory processes and pain associated with endometriosis. By inhibiting mPGES-1, vipoglanstat aims to reduce inflammation and alleviate pain without the systemic effects often associated with hormonal therapies. Preclinical studies have demonstrated that vipoglanstat significantly reduces both pain-related behaviors and the size of endometriotic lesions in animal models. Previous clinical investigations have also indicated that the drug is safe and well-tolerated in humans, paving the way for this Phase II trial.
The NOVA Trial: Design and Objectives
The NOVA trial is a double-blind, placebo-controlled, randomized study designed to assess the safety and efficacy of two different doses of vipoglanstat compared to a placebo. Approximately 190 women aged 18 to 45 years, diagnosed with moderate to severe endometriosis-related pain, will be enrolled across various European regions. Participants will receive either vipoglanstat or a placebo orally over four menstrual cycles. The primary endpoint of the study is the reduction in endometriosis-related pain during non-menstrual days.
Beyond pain reduction, the trial will also evaluate secondary endpoints, including the impact of vipoglanstat on pain during sexual intercourse (dyspareunia), period pain (dysmenorrhoea), the use of opioid rescue medication, and patient-reported quality of life. Researchers will also utilize magnetic resonance imaging (MRI) to assess changes in the size and characteristics of endometriotic lesions. Top-line results from the NOVA trial are anticipated in 2027, offering a crucial data set for future development and potential regulatory submissions.
The Need for Non-Hormonal Alternatives
Current treatments for endometriosis often rely on hormonal therapies, such as birth control pills, GnRH agonists, and progestins. While these treatments can be effective in managing symptoms for some women, they can also be associated with undesirable side effects, including mood swings, weight gain, and bone loss. Hormonal therapies do not address the underlying disease pathology and often require long-term use. Opioid pain medications are sometimes prescribed for severe pain, but carry the risk of addiction and other adverse effects. The development of a non-hormonal, non-opioid treatment like vipoglanstat represents a significant opportunity to address the unmet needs of women with endometriosis.
Gesynta Pharma’s Commitment to Innovation
According to a statement released by Gesynta Pharma, CEO Patric Stenberg emphasized the importance of the NOVA trial, stating that dosing the first patient represents “a major milestone in developing vipoglanstat, aiming at providing a game-changer in the treatment of endometriosis.” He further noted that the trial is designed to provide “robust, controlled data on pain relief and quality of life for women with moderate to severe disease,” building on a “solid preclinical basis and positive clinical data on safety, tolerability, and pharmacokinetics.”
What’s Next for Vipoglanstat and Endometriosis Research?
The completion of the NOVA trial and the subsequent analysis of its results will be critical in determining the future of vipoglanstat. If the trial demonstrates significant efficacy and a favorable safety profile, Gesynta Pharma may pursue further clinical trials, potentially leading to regulatory approval and eventual market availability. Ongoing research into the underlying causes of endometriosis and the development of novel therapies remains a priority for the medical community. The National Institutes of Health (NIH) provides extensive information on endometriosis and ongoing research initiatives through its website: https://www.nichd.nih.gov/health/topics/endometri/conditioninfo.
The progress of the NOVA trial will be closely watched by both the medical community and the millions of women worldwide affected by endometriosis. The potential for a new, targeted, and well-tolerated treatment offers a beacon of hope for improved management of this debilitating condition.
Stay informed: We will continue to follow the development of vipoglanstat and provide updates as new information becomes available. Share your thoughts and experiences with endometriosis in the comments below.